Tag: Immuno
OSE Immuno: end of recruitment for a phase 1/2 trial – 07/11/2023 at 18:09
(CercleFinance.com) – OSE Immunotherapeutics and the Center Hospitalier Universitaire de Nantes announce the end of patient recruitment in the FIRsT study, a phase 1/2 clinical trial. This is the first…
Ose immuno: End of recruitment for a phase 1/2 trial
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
OSE Immuno: end of recruitment for a phase 1/2 trial
(CercleFinance.com) – OSE Immunotherapeutics and the Center Hospitalier Universitaire de Nantes announce the end of patient recruitment in the FIRsT study, a phase 1/2 clinical trial. This is the first…
Ose immuno: Driven by a new patent for its anti-lung cancer, OSE Immuno is progressing on the stock market
(BFM Bourse) – The Nantes biotechnology company announced on Tuesday evening that it had expanded its patent portfolio internationally. OSE Immunotherapeutics has indeed obtained a new patent in the United…
Ose Immuno: received a new patent from the USPTO – 07/05/2023 at 08:13
(CercleFinance.com) – OSE Immunotherapeutics announces that the United States Patent and Trademark Office (USPTO) has granted it a new patent protecting Tedopi®, its therapeutic cancer vaccine, for the treatment of…
Ose Immuno: new US patent protecting Tedopi until 2037
(CercleFinance.com) – OSE Immunotherapeutics announces that the United States Patent and Trademark Office (USPTO) has granted it a new patent protecting Tedopi®, its therapeutic cancer vaccine, for the treatment of…
OSE Immuno: receives funding of 1.5 ME from Bpifrance – 06/20/2023 at 18:09
(CercleFinance.com) – OSE Immunotherapeutics announces today that the Company has received non-dilutive financing of €1.5 million from Bpifrance – Direction Régionale de Nantes. This funding aims to accelerate the development…
OSE Immuno: receives funding of 1.5 ME from Bpifrance
(CercleFinance.com) – OSE Immunotherapeutics announces today that the Company has received non-dilutive financing of €1.5 million from Bpifrance – Direction Régionale de Nantes. This funding aims to accelerate the development…
OSE Immuno: Eric Leire should join the Board of Directors
By Alexandra Saintpierre Published on 05/31/2023 at 6:16 p.m. (Boursier.com) — The Board of Directors ofOSE Immunotherapeutics,…
OSE Immuno: end of patient recruitment in the phase 2 clinical trial evaluating Tedopi in advanced pancreatic cancer
By Alexandra Saintpierre Published on 05/24/2023 at 6:19 p.m. (Boursier.com) — OSE Immunotherapeutics SA announces the end…
OSE Immuno: early access authorization for Tedopi in Spain
(CercleFinance.com) – OSE Immunotherapeutics announces today that AEMPS, the Spanish Medicines Agency, has made available a new early access program which will allow patients to have access to Tedopi® within…
OSE Immuno: start of a first human trial – 22/12/2022 at 12:11
(CercleFinance.com) – OSE Immuno announced on Thursday that it had treated a first patient with its anti-PD1 monoclonal antibody as part of the start of a phase 1/2 trial devoted…